Laurie Slovarp, PhD, CCC-SLP

CONTACT

Lead Sponsor

Hyfe Inc

Age

21 - No limit years

Sex

ALL

Healthy Volunteers

No

•Age 21 or older.
•Currently suffering from a cough that started at least 8 weeks ago that is largely unproductive (i.e., at least 50% of the time the cough produces zero mucus that needs to be spit out or swallowed).
•Normal chest X-ray or chest CT scan at some point that was prescribed specifically for their cough.
•At least one physician visit for cough with standard-of-care therapy but inadequate symptom relief.
•Stability of treatment: willing to avoid new cough treatments during study or report changes if they occur.
•Ability to comply: willing/able to wear the watch daily for the required duration of study and to complete all required questionnaires.
•Informed consent: understanding of the study procedures and agreement to comply with protocol.

•Recent upper respiratory infection (past 4 weeks).
•History of hemoptysis (coughing up blood) since onset of the current cough.
•Current smoker (incl. vaping) of any substance.
•≥10 consecutive pack-years smoking history within \<10 years prior to screening.
•Diagnosed with a chronic lung condition (COPD, emphysema, lung cancer, IPF, chronic bronchitis, asthma). Note: Suspected asthma without confirmed diagnosis or benefit from asthma therapy is not an exclusion.
•Current or past head/neck cancer.
•Difficulty swallowing.
•On ACE inhibitors, such as Benzapril (Lotensin), Captopril (Capoten), Enalapril/Enalaprilat (Vasotec oral and injectable), Fosinopril (Monopril), Lisinopril (Zestril and Prinivil), Moexipril (Univasc), Perindopril (Aceon), Quinapril (Accupril), Ramipril (Altace), and Trandolapril (Mavik)
•Prior treatment for cough by a speech-language pathologist.
•Living with another individual with a frequent cough that would interfere with monitoring.
•Participation in any cough intervention study within 30 days or 5 half-lives of the intervention.
•Major scheduled surgery during the study period.